Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Forodesine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Forodesine SCHEMBL17161840 | 1.00 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15525350 | 1.00 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15718038 | 1.00 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL2292668 | 0.99 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15740194 | 0.99 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15318145 | 0.99 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15373311 | 0.99 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL21386033 | 0.99 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL3896676 | 0.99 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15740309 | 0.99 | PNP (1.00) | PNPHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251674-A2 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BioCryst Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | MIDCAP FINANCIAL TRUST, AS AGENT | 2017-09-21 | — | — | US | disclosed |
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BIOCRYST PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | PNP 17/4885HPRT1 147/4885 |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | PNP 17/4885HPRT1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.